Multi-Omics Blood Test Detects Nine Cancer Types with 75% Accuracy
New liquid biopsy combining DNA methylation and protein markers shows promise for early multi-cancer detection across nine major cancer types.
Summary
Researchers developed a blood test that can detect nine different cancer types by analyzing DNA methylation patterns and protein markers together. The PROMISE study tested 1,706 participants and found that combining these biomarkers achieved 75% sensitivity at 99% specificity for cancer detection. While DNA methylation alone performed well, adding protein markers improved detection rates, especially for liver and ovarian cancers. The test also correctly identified the cancer's origin in 73% of cases, reaching 100% accuracy for liver and ovarian cancers when methylation tests were negative.
Detailed Summary
Early cancer detection could revolutionize health outcomes by catching tumors when they're most treatable. Current screening methods are limited to specific cancer types, leaving many cancers undetected until advanced stages.
The PROMISE study investigated whether combining multiple biological markers could create a comprehensive blood test for nine cancer types: head/neck, esophageal, lung, stomach, liver, biliary tract, pancreatic, colorectal, and ovarian cancers. Researchers analyzed blood samples from 1,706 participants, comparing DNA methylation patterns, genetic mutations, and protein levels.
The multi-omics approach achieved 75% sensitivity with 99% specificity, meaning it correctly identified three-quarters of cancer cases while producing very few false positives. DNA methylation patterns proved most effective, detecting 95% of cases found by mutation analysis. However, protein markers provided unique value, identifying 14% of cases missed by methylation alone. The test also determined cancer origin with 73% accuracy overall, reaching perfect accuracy for liver and ovarian cancers when methylation tests were negative.
This technology could enable routine cancer screening through simple blood draws, potentially catching cancers years before symptoms appear. Early detection dramatically improves survival rates and treatment options while reducing healthcare costs. The high specificity minimizes unnecessary anxiety and procedures from false positives.
However, the study was conducted in Chinese populations, and results may not generalize globally. The 75% sensitivity means one in four cancers could still be missed, and the technology requires validation in larger, more diverse populations before clinical implementation.
Key Findings
- Multi-omics blood test achieved 75% cancer detection sensitivity with 99% specificity across nine cancer types
- Protein markers identified 14% of cancers missed by DNA methylation analysis alone
- Test correctly identified cancer origin in 73% of cases, reaching 100% for liver and ovarian cancers
- DNA methylation outperformed both mutation and protein-based detection methods individually
Methodology
Prospective study of 1,706 participants (840 healthy, 866 cancer patients) with blood samples randomly divided into training and validation sets. Multi-omics analysis included circulating cell-free DNA methylation, genetic mutations, and protein biomarkers across nine cancer types.
Study Limitations
Study conducted only in Chinese populations, limiting global generalizability. 25% of cancers still go undetected, and larger validation studies in diverse populations are needed before clinical implementation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.